NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 107 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.00 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $71,433 | -18.7% | 17,508 | 0.0% | 0.00% | – |
| Q4 2022 | $87,890 | -59.6% | 17,508 | +5.3% | 0.00% | – |
| Q3 2022 | $217,403 | -0.0% | 16,621 | -2.0% | 0.00% | – |
| Q2 2022 | $217,466 | -3.0% | 16,963 | +15.4% | 0.00% | – |
| Q1 2022 | $224,114 | -29.1% | 14,696 | -17.7% | 0.00% | – |
| Q4 2021 | $316,000 | -15.1% | 17,864 | +1.1% | 0.00% | – |
| Q3 2021 | $372,000 | -0.5% | 17,676 | -6.8% | 0.00% | – |
| Q2 2021 | $374,000 | -17.8% | 18,968 | +21.3% | 0.00% | – |
| Q1 2021 | $455,000 | -3.2% | 15,641 | +0.8% | 0.00% | – |
| Q4 2020 | $470,000 | +95.8% | 15,518 | +3.0% | 0.00% | – |
| Q3 2020 | $240,000 | -18.6% | 15,071 | 0.0% | 0.00% | – |
| Q2 2020 | $295,000 | +43.2% | 15,071 | -9.6% | 0.00% | – |
| Q1 2020 | $206,000 | – | 16,668 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |